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Although CD133 has been shown to be a marker for cancer stem cells in various tumours, its expression in pancreatic cancer has not
yet been clinically reported. In this study, we investigated the relationship between CD133 expression and clinicopathological factors
in pancreatic cancer. Pancreatic head carcinoma specimens from 80 patients who underwent surgical resection were
immunohistochemically assessed for CD133, vascular endothelial growth factor (VEGF)-C, CXCR4, CD34, Ki-67, and cytokeratin
(CK) expressions. Sixty percentage (48/80) of specimens were CD133-positive, with less than 15% cells per specimen expressing the
marker. CD133-positive cells were found at the peripheral site of adenocarcinoma glandular structures and were negative for CK.
There was a significant correlation between CD133 expression and clinicopathological factors, including histological type, lymphatic
invasion, and lymph node metastasis (P¼0.0215, 0.0023, and 0.0024, respectively). Vascular endothelial growth factor-C expression
was also significantly correlated with CD133 expression (P¼0.0002). Consequently, the 5-year survival rate of CD133-positive
patients was significantly lower than that of CD133-negative patients (P¼0.0002) and multivariate analysis revealed that CD133
expression was an independent prognostic factor (P¼0.0103). These results suggest that CD133 expression in pancreatic cancer
was significantly associated with lymphatic metastasis, VEGF-C expression, and prognosis.
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Pancreatic adenocarcinoma patient survival rates are lower than
those of other forms of gastrointestinal malignancies (Silverberg and
Lubera, 1988). This could be because of the propensity for early
metastasis to regional lymph nodes and the liver, as the presence or
absence of lymph node metastasis is an important prognostic factor
for patients with pancreatic cancer (Maeda et al,2 0 0 7 ) .
The existence of cancer stem cells (CSCs) was first demonstrated
by transplantation of a small population of harvested leukaemia
cells from patients into immunedeficient mice, which then
developed the same cancer (Bonnet and Dick, 1997). Since then,
recent evidence suggests that a subset of cells within a tumour has
stem-like characteristics, including the ability to initiate tumours,
high proliferative rates, a high capacity of self-renewal, and the
propensity to differentiate into actively proliferating tumour cells
(Reya et al, 2001; Presnell et al, 2002; Pardal et al, 2003). These
stem-like tumour cells are often associated with elevated expres-
sion of the stem cell surface marker CD133 (Neuzil et al, 2007).
CD133 (AC133) is a highly conserved antigen and the human
homologue of mouse Prominin-1, which was originally identified as
a 5-transmembrane cell surface glycoprotein expressed in a
subpopulation of CD34þ haematopoietic stem and progenitor cells
derived from human fetal liver and bone marrow (Miraglia et al,
1997; Yin et al, 1997). CD133 expression has been detected in several
normal tissues including neuroepithelium, embryonic and adult
immature epithelia (Weigmann et al, 1997; Corbeil et al, 2000;
Richardson et al, 2004; Shmelkov et al, 2005). The association
between CD133 and CSCs has been documented in haematological
malignancies (Horn et al, 1999) and since then, CD133 expression
has been identified in various types of solid tumours, including
brain tumours (Singh et al, 2003, 2004; Beier et al, 2007), prostate
cancer (Collins et al,2 0 0 5 ) ,k i d n e yc a n c e r( F l o r e ket al, 2005),
melanoma (Klein et al, 2007; Monzani et al, 2007), ovarian cancer
(Ferrandina et al, 2007), hepatocellular carcinoma (Suetsugu et al,
2006; Ma et al, 2007; Yin et al, 2007), and colon cancer (Ieta et al,
2007; O’Brien et al, 2007; Ricci-Vitiani et al, 2007).
Transplantation experiments have clearly shown that the
behaviour of CD133-positive cancer cells differs from that of
CD133-negative cancer cells. For example, transplantation of as
few as 100 CD133
þ glioblastoma cells successfully induced
tumours in immunodeficient mice, whereas transplantation of
1 10
5 CD133
  cells isolated from the same tumour failed to do so
(Singh et al, 2004). Moreover, CD133
þ and CD133
  glioblastoma-
derived cells showed differential growth characteristics and
molecular profiles (Beier et al, 2007). CD133
þ cancer cells of
glioma exhibited resistance to radiation (Bao et al, 2006a). In
prostate cancer, a CSC population with the CD44
þ/integrina2b1
hi/
CD133
þ phenotype has been identified that exhibits extensive
proliferation, self-renewal, differentiation, and invasion (Collins
et al, 2005). In colon cancer, a small number of CD133
þ cells can
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smaintain themselves as well as differentiate and re-establish
tumour heterogeneity after serial transplantation (O’Brien et al,
2007; Ricci-Vitiani et al, 2007). CD133
þ cells in colon cancer cell
lines have a high degree of tumorigenic ability in vivo, and their
levels of proliferation, colony formation, and invasive ability were
found to be higher than those of CD133
  cells in vitro (Ieta et al,
2007). There are also small populations of CD133
þ cells in human
hepatocellular carcinoma (HCC) cell lines and primary HCC
tissues (Yin et al, 2007). In contrast with these findings, it was
reported that as many as half of Huh-7 cells, a human liver cancer
cell line, are CD133
þ (Suetsugu et al, 2006). The CD133
þ cells
possess a greater colony-forming efficiency, higher proliferative
output, and greater ability to form tumour in vivo (Ma et al, 2007).
Elevated CD133 expression was found in two of five pancreatic
carcinoma cell lines (Olempska et al, 2007). Furthermore, a recent
report demonstrated that a subpopulation of CD133
þ CXCR4
þ
cells was responsible for tumour metastasis (Hermann et al, 2007).
CD133 mRNA expression appears to be an independent
prognostic factor for overall survival, as increased levels were
detected in the peripheral blood of cancer patients with bone
metastasis (Mehra etal, 2006) and were shown to predict colon
cancer recurrence (Lin et al, 2007). Tumorigenic cells display
unique surface marker patterns, such as CD44
þ in head and neck
squamous cell carcinoma (Prince et al, 2007), epithelial cell
adhesion molecule (EPCAM)
high CD44
þ in colon cancer (Dalerba
et al, 2007), CD44
þ integrina2b1
þ in prostate cancer cells
(Patrawala et al, 2007), CD44
þ CD24
 /low epithelial-specific
antigen (ESA)
þ (Al-Hajj et al, 2003), CD44
þ CD24
 /low (Ponti
et al, 2005) in breast cancer associated with distant metastasis
(Abraham et al, 2005), and CD44
þ CD24
þ ESA
þ in pancreatic
cancer (Li et al, 2007).
However, the possible clinical significance of CD133 expression
in pancreatic cancer has not been investigated using immunohis-
tochemistry, which is considered a difficult technique because of
the inability to detect small numbers of putative stem cells (Miki
et al, 2007). Nevertheless, immunostained cells may reflect the
original features of cells in the tissue, so we used this approach in
the present study to detect CD133-positive cells in paraffin-
embedded specimens from pancreatic cancer patients. CD133-
positive sections were also subjected to analysis of vascular
endothelial growth factor (VEGF)-C expression. The purpose of
this study was (i) to examine the expression of CD133 in surgical
specimens of pancreatic head carcinoma by immunohistochemical
methods, (ii) to explore possible correlation between CD133
expression and clinicopathological variables, (iii) to correlate
expression of CD133 with VEGF-C, and (iv) to determine the
prognostic value of CD133 expression.
MATERIALS AND METHODS
Patients and specimens
Eighty patients (52 male and 28 female) who underwent surgical
treatment at Kagoshima University Hospital, Kagoshima, Japan for
invasive ductal adenocarcinoma of the pancreatic head were
included in the study. The patient age range was 42–80 years
(mean 66.0 years). All patients underwent macroscopically curative
resection by total pancreatectomy, pancreaticoduodenectomy, or
pylorus-preserving pancreaticoduodenectomy with lymph node
dissection. No preoperative chemotherapy or radiotherapy was
administered. Cancer tissue specimens were collected from the
patients after informed consent had been obtained, in accordance
with the institutional guidelines of our hospital. The number of
patients with pT1, pT2, pT3, and pT4 tumours was three (3.8%),
four (5.0%), 65 (81.3%), and eight (10.0%), respectively.
Resected primary tumours and lymph nodes were histologically
examined by haematoxylin and eosin staining using the
tumour-node-metastasis classification system (Sobin and
Wittekind, 2002). Histologically, all of the tumours were invasive
ductal adenocarcinomas (35 well differentiated, 42 moderately
differentiated, and three poorly differentiated). Lymphatic and
venous invasions were observed in 69 (86.3%) and 61 tumours
(76.3%), respectively. Lymph node metastasis was present in 51
tumours (63.8%).
All patients were assessed by radiography, ultrasonography, and
computed tomography every 3 months after discharge. New
lesions detected by imaging were considered indicative of relapse.
The median follow-up period was 20 months (range 6–168
months). During this period, 29 patients experienced recurrence
of liver disease (36.3%).
Immunohistochemistry
Primary lesions were fixed in 10% formaldehyde, embedded in
paraffin, and cut into five 3-mm thick sections every 30mm.
Sections were deparaffinised in xylene, rehydrated in a graded
series of ethanol, and incubated in 3.0% hydrogen peroxide in
methanol for 10min to block endogenous peroxidase action. Slides
were heated at 1001C in a microwave oven in 10mM sodium citrate
(pH 6.0) for 10min and cooled to room temperature. After
incubation in 1% bovine serum albumin for 30min at room
temperature, sections were incubated overnight at 41C with an
anti-CD133 goat polyclonal antibody (Santa Cruz Laboratory,
Santa Cruz, CA, USA; diluted 1:200 in phosphate-buffered saline
(PBS)), anti-VEGF-C goat polyclonal antibody (Santa Cruz
Laboratory; diluted 1:200 in PBS), anti-CXCR4 mouse monoclonal
antibody (R&D Systems, Minneapolis, MN, USA; diluted 1:200 in
PBS), and anti-CD34 mouse monoclonal antibody (DAKO
Corporation, Carpinteria, CA, USA; diluted 1:100 in PBS) for
immunostaining microvessels.
The 3-mm thick paraffin sections of primary tumours were
deparaffinised, treated with the heat-induced antigen retrieval
technique, and epithelial pancreatic carcinoma cells were im-
munostained for 60min using cytokeratin (CK) AE1/AE3 (20:1
ratio of AE1 to AE3, DAKO Corporation; diluted 1:200 in PBS), a
mouse monoclonal antibody cocktail that reacts with all epithelial
cells of normal pancreatic duct and tumour cells (Pasquinelli et al,
1995; Kurahara et al, 2007), and Ki-67 mouse monoclonal antibody
(DAKO Corporation; diluted 1:50 in PBS) that reacts with
proliferating cells at any phase of the cell cycle (except for G0
phase) (Igarashi et al, 1999). Reactions were developed using the
avidin–biotin immunoperoxidase technique (ABC method; Hsu
et al, 1981). Immunoreactivity was visualised using the Vectastain
Elite ABC kit and a 3,30-diaminobenzidine solution (Vector
Laboratories Inc., Burlingame, CA, USA). Sections were then
briefly counterstained with haematoxylin.
All immunostained slides were inspected by two independent
observers (SM and ST), who had no prior knowledge of the
clinicopathological findings. Ten fields (inside the tumour and in
the area exhibiting tumour invasion) were selected, and expression
was evaluated in 1000 tumour cells (100 cells per field) with high-
power ( 200) microscopy. Specimens were defined as positive for
CD133 expression if there were tumour cells distinctly stained
by anti-CD133 antibody. The presence of VEGF-C and CXCR4
immunoreactivity in over 10% of tumour cells was defined as
positive expression. Immunostaining for CD34 was assessed to
determine microvessel density (MVD) (Weidner et al, 1991; Maeda
et al, 2007; Mohammed et al, 2007). Vessels in the five most highly
visualised areas (0.785mm
2 per field) by CD34 immunostaining
were counted under a  200 light microscope. The tumour MVD
was calculated as the mean value of five fields.
Statistical analyses
Group differences were statistically analysed using the w
2 test and
t-test. The Kaplan–Meier method was used to analyse survival,
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sand the log-rank test was used to estimate differences in survival.
Prognostic factors were examined using univariate and multi-
variate analyses (Cox proportional hazards regression model).
P-values less than 0.05 were considered statistically significant. All
statistical analyses were performed using StatView statistical
software version 5.0 (SAS Institute Inc., Cary, NC, USA).
A B
C D
Figure 1 Immunohistochemical staining for CD133 and CK in invasive ductal adenocarcinoma of the pancreas head. (A) Normal pancreatic ductal
epithelium cells were not stained for CD133. (B) The ductal epithelium cells in the consecutive slices of (A) were clearly stained by CK antibody. (C)
CD133 expression appeared to be present at the peripheral portions (facing the interstitial space) of the glandular structures of adenocarcinoma. The
percentage of immunoreactive cells (arrows) was estimated to be less than 5% of the tumour cells. (D) The CK antibody clearly reacted with the CD133-
negative cells of adenocarcinoma, but not with the CD133-positive cells (arrowheads) in the consecutive slices of (C). Scale bars, 100mm.
AB
CD
Figure 2 (A) CD133 expression (arrows) appeared to be present in the peripheral portions of the glandular structures. The percentage of
immunoreactive cells (arrows) was estimated to be more than 5% of the tumour cells. (B) The CK antibody clearly reacted with the CD133-negative cells of
adenocarcinoma, but not with the CD133-positive cells (arrowheads) in the consecutive slices of (A). (C) CD133 expression was observed mainly in the
cytoplasm of tumour cells (arrows). Shown is a magnified figure described in (A) as a box. (D) CD133-positive cells were unreactive with the CK antibody
(arrowheads) in the consecutive slices of (C). Shown is a magnified figure described in (B) as a box. Scale bars, 100mm( A and B), 20mm (C and D).
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sRESULTS
Expression of CD133 and CK in pancreatic head carcinoma
specimens
No CD133 immunoreactivity was observed in normal pancreatic
ductal epithelium (Figure 1A), which was clearly stained by the CK
antibody (Figure 1B). CD133-positive tumour cells were present in
the peripheral site (facing interstitial space) of adenocarcinoma
glandular structures in patient samples with both less than
(Figure 1C, arrows) and more than 5% CD133-positive tumour
cells (Figure 2A, arrows). CD133-negative cells of adenocarcinoma
were CK-positive, but CD133-positive cells were not (Figure 1D,
arrowheads; Figure 2B and D, arrowheads), which is consistent
with previous findings (Hermann et al, 2007). Notably, positive
CD133 expression was observed in the cytoplasm of carcinoma
cells (Figure 2C, arrows).
CD133 expression was classified into five levels: negative (0%),
less than 5, 5–10, 11–15, and more than 15% (Figure 3). Forty-
eight (60.0%) of 80 specimens were CD133-positive and the
percentage of CD133-positive cells per specimen was less than 15%
(Figure 3).
Correlation between CD133 expression and
clinicopathological factors
As shown in Table 1, CD133 expression was significantly
correlated with clinicopathological parameters, including histolo-
gical type (P¼0.0215), lymphatic invasion (P¼0.0023), and
lymph node metastasis (P¼0.0024). However, there was no
significant association between CD133 expression and age, gender,
tumour depth, cancer stage, venous invasion, or liver metastasis
(Table 1).
Relationship between CD133 and VEGF-C expression
When we correlated expression of CD133 with VEGF-C in
pancreatic cancers, we observed a significant association between
CD133 expression and VEGF-C expression (P¼0.0002; Table 2). In
Figure 4A, a typical pattern of VEGF-C-positive expression is
shown as an example in the consecutive slices of Figure 1C.
Relationship between CD133 and CXCR4 expression
We next examined the correlation between CD133 and CXCR4
expression as it was recently demonstrated that CD133
þ CXCR4
þ
cells are involved in tumour metastasis (Hermann et al, 2007).
Eighty-five percentage (68 out of 80) of specimens tested exhibited
positive expression for CXCR4. Notably, positive expression of
CXCR4 was observed in all epithelial cells of adenocarcinoma. In
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Figure 3 Classification of CD133-positive expression in the invasive
ductal adenocarcinoma of the pancreas head samples from 80 patients.
Tumour samples were classified into five groups (negative (0%), o5, 5–10,
11–15, and 415%) based on the percentage of stained cells.
Table 1 Correlation between CD133 expression and clinicopathologic
factors in pancreatic head carcinoma
CD133 expression
Positive Negative
Total n¼48 n¼32
n¼80 (%) 60.0% 40.0% P-value
Age (years)
Mean±s.d. 65.5±9.9 66.8±8.8 0.6908
Gender
Male 52 (65.0) 34 (70.8) 18 (56.3) 0.1803
Female 28 (35.0) 14 (29.2) 14 (43.8)
Histology
Well 35 (43.8) 15 (31.3) 20 (62.5) 0.0215
Moderately 42 (52.5) 31 (64.6) 11 (34.4)
Poor 3 (3.8) 2 (4.2) 1 (3.1)
pT
pT1 3 (3.8) 1 (2.1) 2 (6.3) 0.3607
pT2 4 (5.0) 1 (2.1) 3 (9.4)
pT3 65 (81.3) 41 (85.4) 24 (75.0)
pT4 8 (10.0) 5 (10.4) 3 (9.4)
pN
Negative 29 (36.3) 11 (22.9) 18 (56.3) 0.0024
Positive 51 (63.8) 37 (77.1) 14 (43.8)
Liver metastasis
Negative 51 (63.8) 28 (58.3) 23 (71.9) 0.2171
Positive 29 (36.3) 20 (41.7) 9 (28.1)
pStage
I 6 (7.5) 2 (4.2) 4 (12.5) 0.3540
IIA 22 (27.5) 11 (22.9) 11 (34.4)
IIB 42 (52.5) 29 (60.4) 13 (40.6)
III 6 (7.5) 4 (8.3) 2 (6.3)
IV 4 (5.0) 2 (4.2) 2 (6.3)
Lymphatic invasion
Negative 11 (13.8) 2 (4.2) 9 (28.1) 0.0023
Positive 69 (86.3) 46 (95.8) 23 (71.9)
Venous invasion
Negative 19 (23.8) 9 (18.8) 10 (31.3) 0.1981
Positive 61 (76.3) 39 (81.3) 22 (68.8)
s.d.¼standard deviation.
Table 2 Correlation between expression of CD133 and expression of
VEGF-C and CXCR4 in pancreatic head carcinoma
CD133 expression
Positive
expression
n¼48 (%)
Negative
expression
n¼32 (%) P-value
VEGF-C expression
Negative (n¼35) 13 (27.1) 22 (68.8) 0.0002
Positive (n¼45) 35 (72.9) 10 (31.3)
CXCR4 expression
Negative (n¼12) 8 (16.7) 4 (12.5) 0.6091
Positive (n¼68) 40 (83.3) 28 (87.5)
VEGF-C¼vascular endothelial growth factor-C.
CD133 in pancreatic cancer
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as an example in the consecutive slices of Figure 1C. The collective
data indicate that CXCR4 expression was not associated with
CD133 expression (P¼0.6091; Table 2). Furthermore, in the
CD133-positive group, there was no significant association
between CXCR4 expression and lymph node metastasis
(P¼0.4425) or lymphatic invasion (P¼0.5182).
Relationship between CD133 and Ki-67 expression
When the consecutive slices (of Figure 2A) were reacted with Ki-67
antibody demonstrating proliferating cells, some CD133-positive
cells were reactive with Ki-67 antibody (Figure 4C, arrows), but
other cells were unreactive (Figure 4C, arrowheads).
Relationship between CD133 expression and MVD
We next correlated expression of CD133 with density of
microvessels in pancreatic cancers. Microvessels were delineated
by staining with the CD34 antibody. In Figure 4D, tumour with
MVD is shown as an example. Notably, MVD was significantly
(P¼0.0467) higher in CD133-positive tumours (mean±s.d.¼
43.64±11.26) than in CD133-negative tumours (38.18±11.71;
Figure 5).
Prognostic impact of CD133 expression
We examined a possible correlation between patient prognosis and
the percentage of CD133-positive cells. The 5-year survival rate of
patients with CD133-negative tumours was 23.5%, that of patients
with less than 5% CD133-positive cells was 3.4%, and that of
patients with more than 5% CD133-positive cells was 0.0%. This
finding produced a significant difference in the 5-year survival rate
between patients with tumours positive or negative for CD133
expression (P¼0.0002; Figure 6), and between patients with more
or less than 5% cells expressing CD133 (P¼0.0366; Figure 6).
In the CD133-positive group, there was no significant difference
in the 5-year survival rate between those patients who were
positive or negative for CXCR4 expression (P¼0.2176; Figure 7).
Patient prognosis
Tables 3 and 4 show the results of univariate and multivariate
analyses relating to patient prognosis. Univariate analysis demon-
strated that postoperative survival was significantly related to
C D
A B
Figure 4 Immunohistochemical staining for VEGF-C, CXCR4, Ki-67, and CD34 in invasive ductal adenocarcinoma of the pancreas head. (A) Positive
expression of VEGF-C was observed in the cytoplasm of all tumour cells. (B) Positive expression of CXCR4 was seen in all epithelial cells of
adenocarcinoma. (C) Ki-67-positive expression was observed in the nuclei of certain CD133-positive cells (arrows). Some CD133-positive cells were
negative for staining with Ki-67 (arrowheads). (D) Expression of CD34 was detected in microvessels. The sections shown in (A) and (B) are the consecutive
slices of Figure 1C, and those shown in (C) and (D) are the consecutive slices of Figure 2A. Scale bars, 100mm.
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Figure 5 Microvessel density counts after observation of anti-CD34-
stained samples (0.785mm
2 per field) under a microscope with  200
power. The MVD (mean±s.d.) of the CD133-positive specimens was
significantly different from that of the CD133-negative specimens
(43.64±11.26 vs 38.18±11.71; P¼0.0467).
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stage, and CD133 expression (Po0.05). Multivariate regression
analysis found CD133 expression to be an independent prognostic
factor, but lymph node metastasis and tumour depth were not.
DISCUSSION
Recently, it was hypothesised that tumours comprise heteroge-
neous populations of cells that differ in their abilities to proliferate
and exhibit self-renewal. Only a small number of cells, so-called
CSCs, can proliferate and exhibit extensive self-renewal; most
tumour cells have a limited ability to do so and tend to
differentiate into cells that form the tumour mass (Reya et al,
2001; Presnell et al, 2002; Pardal et al, 2003). Cancer stem cells
appear to be able to initiate and drive tumour growth in different
haematological and solid tumours. CD133, a recently reported
prospective marker for CSC, is expressed in a variety of tumours.
However, to our knowledge, no attempt has been made to detect
CD133 expression in pancreatic cancer specimens.
In this study, we used immunohistochemical staining to detect
positive expression of CD133 in 60% of 80 pancreatic head
carcinoma specimens, and found that the percentage of CD133-
positive cells per specimen was less than 15%. These data are in
agreement with the finding that CSCs represent only a very small
portion of the total tumour cell population. For example, CD133-
positive cells were detected in 0.7–6.1% (Ricci-Vitiani et al, 2007),
1.8–24.5% (O’Brien et al, 2007), 0.3–3% (Todaro et al, 2007) of
primary colon cancer cells, and in 0.7–3.2% of primary pancreatic
cancer cells using flow cytometric analysis (Hermann et al, 2007).
Immunohistochemical staining revealed CD133 expression in
1–3% of hepatocellular carcinoma specimens (Ma et al, 2007).
Notably, we observed no staining for CD133 in normal pancreatic
ductal epithelium in the present study (Figure 1A). The present
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Figure 6 Kaplan–Meier survival curves for patients with more than 5%
CD133-positive tumours, less than 5% CD133-positive tumours, and
CD133-negative tumours in the pancreatic head carcinomas. There was a
significant difference in the 5-year survival rate between patients with
tumours that were positive and negative for CD133 expression
(P¼0.0002), and between patients with more and less than 5% CD133-
positive tumours (P¼0.0366).
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Figure 7 Kaplan–Meier survival curves for patients with CXCR4-
positive and CXCR4-negative tumours in the CD133-positive group. There
was no significant difference between the patients with tumours that were
positive and negative for CXCR4 expression in the CD133-positive group
(P¼0.2176).
Table 3 Univariate analysis of prognostic factors in pancreatic head
carcinoma
Variables n 5-year survival rate (%) P-value
Age (years)
Over 65 47 10.4 0.4232
Under 64 33 9.6
Gender
Male 52 10.6 0.9762
Female 28 0.0
pT
pT1, 2 7 42.9 0.0417
pT3, 4 73 5.9
pN
Negative 29 20.4 0.0056
Positive 51 3.2
Liver metastasis
Negative 51 14.2 0.0797
Positive 29 3.4
pStage
I, II 70 11.6 0.0073
III, IV 10 0.0
Lymphatic invasion
Negative 11 30.7 0.0334
Positive 69 6.9
Venous invasion
Negative 19 15.8 0.4944
Positive 61 7.3
CD133 expression
Negative 32 23.5 0.0002
Positive 48 2.1
Table 4 Multivariate analyses of prognostic factors in pancreatic head
carcinoma
Independent
factors
Univariate
P
Multivariate
P
Hazard
ratio
95%
confidence
interval
pT
pT1, 2/pT3, 4 0.0417 0.5701 1.355 0.475–3.823
pN
Negative/positive 0.0056 0.2141 1.434 0.812–2.534
CD133 expression
Negative/positive 0.0002 0.0090 2.151 1.211–3.869
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simmunohistochemical data appear to support the hypothesis that
CD133-positive pancreatic carcinoma cells are involved in the
tumorigenic process.
We found that CD133 expression was significantly associated
with histological type, lymphatic invasion, and lymph node
metastasis (Table 1). It is noteworthy that lymph node metastasis
and lymphatic invasion are correlated with CD133 expression, as a
recent study demonstrated that a melanoma cell line highly
enriched with CD133-expressing cells concomitantly expresses
lymphoangiogenic markers, vascular endothelial growth factor
receptor (VEGFR)-3 and lymphatic vessel endothelial hyaluronan
receptor (LYVE)-1 (Monzani et al, 2007). As possible correlation
between VEGF-C expression and lymphangiogenesis has pre-
viously been described (Kurahara et al, 2004; Mohammed et al,
2007), we examined VEGF-C expression in pancreatic cancer
specimens and found it to be significantly associated with CD133
expression (Table 2). This suggests that CD133-positive pancreatic
carcinoma cells promote lymphatic metastasis not only by
inducing lymphangiogenesis, but also by facilitating self-entry
into the lymphatic system. In view of the potential link to
lymphangiogenesis, further studies are needed to address the
possible role of CD133 in lymph node metastasis of pancreatic
cancers.
Recently, the niche microenvironments of CSCs in brain
tumours have been shown to be important for maintaining and
self-renewing CSCs through close interaction with endothelial cells
(Calabrese et al, 2007). In this study, we could not reveal the
histological site of such niches, although we observed that CD133-
positive cells were localised in the peripheral site (facing interstitial
space) of adenocarcinoma glandular structures, and did not
express the epithelial differentiation marker CK (Hermann et al,
2007). Considering the relationship between CD133-positive cells
and lymph node metastasis, lymphangiogenesis and/or lymphatic
vessels might be involved in forming the niche microenvironments
of CSCs for pancreatic cancer. An understanding of niche
histological sites would therefore be of use in preventing
progression of pancreatic cancer cells.
High-grade MVD was more frequently found in CD133-positive
tumours (Figure 5), reflecting a possible effect of CD133 on tumour
vascularity in pancreatic cancer. Bao et al (2006b) made similar
observations that CD133-positive tumour cells were more vascular
than CD133-negative ones. In this context, investigations are
currently underway to examine whether CD133-positive cells
established from primary pancreatic carcinomas express VEGF
more strongly than CD133-negative cells. There is a clear
difference between CD133-positive and CD133-negative cells
derived from pancreatic cancer regarding angiogenic potential.
A specific subpopulation of CD133
þ CXCR4
þ CSCs was
recently identified as being responsible for tumour metastasis
(Hermann et al, 2007). The CXCR4 protein has multiple essential
functions, including homing of stem cells and metastasis of cancer
cells (Miki et al, 2007). Several cancers express CXCR4, and a
relationship between CXCR4 expression and malignant potenti-
ality has been suggested (Muller et al, 2001; Kaifi et al, 2005). In
the present study, 85% of specimens exhibited positive expression
of CXCR4. Notably, positive expression of CXCR4 was observed in
all epithelial cells of adenocarcinoma, which is consistent with
previous observations (Gockel et al, 2006). Furthermore, there was
no significant association between CXCR4 expression and lymph
node metastasis, lymphatic invasion, together with prognosis in
the CD133-positive group. Taking these findings into considera-
tion, it appears that CXCR4 expression is not associated with
CD133 expression, nor with other cancer-related events in the
CD133-positive group.
It remains to be determined whether CD133-positive cancer cells
exhibit higher degrees of proliferative activity than CD133-negative
ones. As a preliminary test, we assessed this possibility using Ki-67
antibody staining and observed the presence of both highly
proliferative activity and less proliferative activity of CD133-
positive cells. To confirm these findings, we are currently
examining the MIB-1 labelling index in CD133-positive and
CD133-negative cells.
In conclusion, our immunohistochemical results indicate that
CD133 expression in pancreatic head cancer is associated with
histological type, lymphatic invasion, lymph node metastasis,
VEGF-C expression, and prognosis. Multivariate survival analysis
revealed that CD133 expression is an independent prognostic
factor. These results suggest that CD133 expression is a useful
marker for predicting the outcome of patients with pancreatic
cancer. This is the first report of an association between CD133
expression and pancreatic cancer. Understanding the biological
function of CD133 expression as a CSC marker in pancreatic
cancer will be helpful in elucidating its role in the pathogenesis of
pancreatic cancer and developing more effective therapeutic
approaches.
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